SEATTLE - Sana Biotechnology, Inc. (NASDAQ:SANA), a biotech firm specializing in engineered cell therapies, has successfully closed an upsized public offering, raising gross proceeds of approximately $189.75 million. The offering involved the sale of 21,772,728 shares of common stock at $5.50 each, including a full exercise of the underwriters' option to purchase an additional 4,500,000 shares. Additionally, pre-funded warrants to purchase 12,727,272 shares were sold at $5.4999 per warrant.
The company, with operations in Seattle, Cambridge, South San Francisco, and Rochester, stated that all of the securities were sold directly by Sana. The funds raised before underwriting discounts, commissions, and other offering expenses will be directed towards advancing Sana's pipeline and general corporate purposes.
Morgan Stanley, J.P. Morgan, Goldman Sachs & Co (NYSE:GS). LLC, and BofA Securities served as the joint book-running managers for the transaction. The offering was conducted according to a Registration Statement on Form S-3, which was previously filed with and declared effective by the Securities and Exchange Commission (SEC). Interested parties were able to access the final prospectus supplement and accompanying prospectus through the SEC's website or directly from the book-running managers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.